Drug Profile
Tigapotide
Alternative Names: PCK 3145 Peptide Therapeutic Program; PCK-3145Latest Information Update: 09 Jul 2013
Price :
$50
*
At a glance
- Originator Ambrilia Biopharma
- Class Antineoplastics; Peptides
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Gelatinase inhibitors; Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Haematological malignancies; Prostate cancer
Most Recent Events
- 09 Jul 2013 No development reported - Phase-II for Prostate cancer in Canada (IV)
- 09 Jul 2013 No development reported - Phase-II for Prostate cancer in United Kingdom (IV)
- 09 Jul 2013 No development reported - Phase-II for Prostate cancer in USA (IV)